The latest price target for Palisade Bio (NASDAQ:PALI) was reported by Maxim Group on May 1, 2024. The analyst firm set a price target for $22.50 expecting PALI to rise to within 12 months (a possible 513.08% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Palisade Bio (NASDAQ:PALI) was provided by Maxim Group, and Palisade Bio reiterated their buy rating.

The last upgrade for Palisade Bio Inc happened on November 17, 2023 when Maxim Group raised their price target to $1.5. Maxim Group previously had a hold for Palisade Bio Inc.

The last downgrade for Palisade Bio Inc happened on August 19, 2022 when Maxim Group changed their price target from N/A to N/A for Palisade Bio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Palisade Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Palisade Bio was filed on May 1, 2024 so you should expect the next rating to be made available sometime around May 1, 2025.

While ratings are subjective and will change, the latest Palisade Bio (PALI) rating was a reiterated with a price target of $0.00 to $22.50. The current price Palisade Bio (PALI) is trading at is $3.67, which is within the analyst’s predicted range.